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and Depression in de novo Parkinson’s disease” 
 
Disentangling the contribution of dysfunction in various neurotransmitter systems to specific clinical 
manifestations in Parkinson’s disease (PD) is an important prerequisite for understanding their 
pathogenesis and for the development of effective treatments. The clinical phenomenology of PD 
encompasses a range of motor and non-motor disorders, of which neuropsychiatric presentations 
such as depression, anxiety, dementia, impulse control disorders and apathy are some of the most 
deleterious for both patients’ and carers’ quality of life. Apathy, characterized by diminished goal-
oriented behaviour, cognition, interests, and emotional expression[Starkstein 2012], is common in 
PD, affecting approximately 40% of patients in cross-sectional studies. It is under-recognised 
[Gallagher et al. 2010] and often confused with dementia or depression, of which it can also be an 
integral part[Pagonabarraga et al. 2015]. Understanding its distinct nature can help improve families’ 
understanding and appropriate management. The underlying pathology of apathy is currently poorly 
understood, although clinical and imaging findings support the role of dopaminergic dysfunction in 
the pathophysiology of apathy in PD [Wen et al. 2016;Magnard et al. 2016] and in patients without 
PD  [Pagonabarraga, Kulisevsky, Strafella, and Krack2015;Starkstein2012]. In this issue Maillet et al, 
for the first time, report on the differential contribution of serotonergic and dopaminergic 
mechanisms to apathy in PD using positron emission tomography (PET) molecular imaging.   
Evidence from animal, biochemical, post-mortem and human in vivo studies have demonstrated loss 
of striatal and extra-striatal serotonin markers in the course of PD indicating that the serotonergic 
system plays a key role in PD pathology [Politis and Niccolini 2015]. The data from the study by 
Maillet et al (2016) support the involvement of serotonergic system also to the development of 
apathy in PD. They used [11C]DASB and [11C]PE2I PET to index presynaptic serotonergic and 
dopaminergic function, respectively, in 15 apathetic and 15 non-apathetic untreated patients with 
PD and in controls. Their findings demonstrate greater serotonergic loss in the basal ganglia in the 
apathetic PD compared to PD patients without apathy, with both PD groups showing reduced 
dopaminergic uptake compared to controls. Moreover, greater serotonergic loss in caudate and 
orbitofrontal cortex correlated with the severity of apathy in patients with PD, whereas apathy was 
not associated with dopaminergic deficits.  
PET is a molecular imaging technique for the quantitative and non-invasive imaging of biological 
functions. The distribution and kinetic profiles of compounds targeting specific biological molecules 
in tissue reflect specific biological functions in the living body. PET used together with specific 
serotonin radioligands has played a major role in elucidating the pathophysiology of serotonergic 
system in PD. Over the past several years, we have seen the development of several PET radioligands 
tagging serotonin targets in the human brain. [18F]MPPF for 5-HT1A receptors, [18F]setoperone for 5-
HT2A receptors and [11C]AZ10419369 for 5-HT1B receptors, and [11C]DASB  to image the 5-HT 
transporter (SERT) are few examples of PET techniques for studying the serotonin system in the 
human brain.  
Studies using [11C]DASB PET have demonstrated that PD pathology is characterised by a progressive 
and non-linear loss of serotonergic terminals, which is slower compared to the dopaminergic 
degeneration. PET molecular imaging has shown that the clinical implications of the serotonergic 
pathology in PD have been associated with the development of non-motor symptom burden  and 
specifically with symptoms of depression, fatigue , weight loss, and visual hallucinations. [11C]DASB 
PET studies suggest that the serotonergic system is also implicated in the development of tremor in 
PD, which has a variable response to dopaminergic treatment, whereas this is not the case for 
bradykinesia and rigidity that are underlined by dopaminergic deficits [Loane et al. 2013]. 
Disturbance of serotonergic relative to dopaminergic innervation in the striatum has also been 
shown to be responsible for the development of levodopa-induced and graft-induced dyskinesias in 
patients with PD[Politis and Niccolini2015], illustrating the interrelation of serotonergic and 
dopaminergic mechanisms in PD. The striatal serotonergic terminals under significant 
overexpression or when there is dopaminergic denervation, such as in PD, become a major source of 
endogenous or levodopa-derived dopamine release[Carta et al. 2007] Serotonergic neurons lack an 
effective mechanism for the regulation of synaptic dopamine levels, which leads to fluctuations in 
synaptic dopamine levels and to pulsatile stimulation of striatal postsynaptic dopamine receptors 
and, subsequently, dyskinesias.  
Maillet et al (2016) findings on apathy add to the list of PD motor and non-motor symptoms and 
complications, which are underlined by serotonergic pathology.  Even in this early cohort, there was 
more pronounced reduction in serotonin transporter (SERT) binding than dopamine 
transporter (DAT) binging in those with apathy, thus challenging the concept of predominantly 
dopaminergic involvement in the early disease stages.  
These imaging findings may change approaches to treatment of apathy in PD. Treatment options for 
apathy are currently limited.  The profound loss of motivation, initiative and low mood, which can 
been seen in patients following withdrawal of dopamine agonists (Dopamine Agonist Withdrawal 
Syndrome, DAWS,[Solla et al. 2015] and following dose reductions after Deep Brain Stimulation for 
PD[Hindle, I et al. 2016], and the improvement after increasing the dosage of dopamine agonist, 
suggest an important role of the dopaminergic system which mediates reward and motivation. 
However, currently there is little evidence from treatment trials for the optimal treatment of apathy 
in PD unrelated to these specific situations. Small controlled studies and case series report 
improvement with dopaminergic medications and noradrenergic and serotonergic antidepressants 
and stimulants. In addition, recently, a small trial with the butyryl cholinesterase inhibitor 
rivastigmine in 30 patients with PD without cognitive impairment reported improvement of apathy 
scores, suggesting a role for cholinesterase inhibitors in the treatment of apathy in PD and for 
cholinergic dysfunction in apathy in PD [Devos et al. 2014].   
The underlying biochemical substrates of apathy are therefore likely to be complex. Coexisting 
syndromes and medications also make interpretation of many clinical and imaging studies difficult. 
Maillet et al (2016) studied de novo PD patients. This avoided difficulties in interpretation of results 
in patients already treated with dopaminergic or serotonergic medications. However, patients also 
had increased depression and anxiety scores, and PET data correlated with apathy severity but also 
with depression and anxiety levels. Previous PET studies have shown that serotonergic mechanisms 
play a role also in these neuropsychiatric disorders and therefore, disentangling these disorders, and 
identifying the pathophysiology of each individual disorder, remains a challenge.  Nevertheless, the 
results of this study suggest that medications acting on serotonergic targets may be efficacious in 
the treatment of apathy and other neuropsychiatric disorders in PD. Whilst a plethora of symptoms 
in PD have now been associated with serotonergic dysfunction, no treatments that specifically target 
these deficits exist. Such agents may provide a future avenue for the treatment of these disorders 
even in early PD. Future studies should additionally explore the involvement of other 
neurotransmitter systems in the development of motor and non-motor symptoms and 
complications in patients with PD. Such examples are the noradrenergic, cannabinoid and 
cholinergic systems, which could be studied with PET molecular imaging together with clinical 
observation.  
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